ArticleProceedings of the National Academy of Sciences of the United States of America1994
Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 296 citations in OpenAlex.
- Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.Diabetes care · 2022Trial
- Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients.Clinical and experimental nephrology · 2011Trial
- Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.Proceedings of the National Academy of Sciences of the United States of America · 2002Trial
- Extracellular Vesicles in Diabetic Cardiomyopathy-State of the Art and Future Perspectives.International journal of molecular sciences · 2024Review
- Novel Fluorometric Assay of Antiglycation Activity Based on Methylglyoxal-Induced Protein Carbonylation.Antioxidants (Basel, Switzerland) · 2023Article
- Protective Effects of Rifampicin and Its Analog Rifampicin Quinone in a Mouse Model of Obesity-Induced Type 2 Diabetes.ACS pharmacology & translational science · 2023Article
- Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?Nutrients · 2022Review
- The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.International journal of molecular sciences · 2022Review
- Role of Glycation in Type 2 Diabetes Mellitus and Its Prevention throughBioMed research international · 2021Review
- Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.Handbook of experimental pharmacology · 2021Article
- Mechanisms of Herbal Nephroprotection in diabetes mellitus.Journal of diabetes research · 2020Review
- Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy.PloS one · 2019Article
- Article
- Sphingosine kinase 1 mediates AGEs-induced fibronectin upregulation in diabetic nephropathy.Oncotarget · 2017Article
- Stimulatory effects of advanced glycation endproducts (AGEs) on fibronectin matrix assembly.Matrix biology : journal of the International Society for Matrix Biology · 2017Article
- Effects of extremely low frequency pulsed magnetic fields on diabetic nephropathy in streptozotocin-treated rats.Biomedical engineering online · 2016Article
- Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.Biomolecules · 2015Review
- Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets.Journal of diabetes research · 2015Review
- Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets.BioMed research international · 2014Review
- -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Several lines of evidence suggest that the excessive accumulation of extracellular matrix in the glomeruli of diabetic kidneys may be due to reactive intermediates forming between glucose and matrix proteins called advanced glycation end products (AGEs). Normal mice received AGE-modified mouse serum albumin i.p. for 4 weeks, and glomerular extracellular matrix, growth factor mRNA levels, and morphology were examined. We found that AGE induced an increase in glomerular extracellular matrix alpha 1(IV) collagen, laminin B1, and transforming growth factor beta 1 mRNA levels, as measured by competitive PCR, as well as glomerular hypertrophy. The AGE response was specific because the coadministration of an AGE inhibitor, aminoguanidine, reduced all these changes. We conclude that AGEs affected expression of genes implicated in diabetic kidney disease and may play a major role in nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.